$520.9 M

COLL Mkt cap, 20-Sep-2018
Collegium Pharmaceutical Net income (Q2, 2018)-31.7 M
Collegium Pharmaceutical EBIT (Q2, 2018)-20.5 M
Collegium Pharmaceutical Cash, 30-Jun-2018133.7 M

Collegium Pharmaceutical Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

R&D expense

8 m14.9 m8.6 m

General and administrative expense

18.9 m80.6 m92.8 m

Operating expense total

26.9 m95.6 m103.9 m

EBIT

(26.9 m)(94.1 m)(75.4 m)

Interest expense

439 k94 k582 k

Interest income

582 k

Net Income

(27.3 m)(94.2 m)(74.9 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

1.6 m3.4 m4.1 m4.3 m2.1 m2.2 m2.3 m4.5 m

General and administrative expense

2.9 m5.9 m11.5 m20.2 m22.8 m22.1 m31.6 m62.9 m

Operating expense total

4.6 m9.3 m15.6 m24.5 m25.3 m24.8 m77 m157.3 m

EBIT

(4.6 m)(9.3 m)(15.6 m)(24.5 m)(23.2 m)(21.3 m)(13.2 m)(20.5 m)

Interest expense

99 k97 k66 k46 k98 k137 k5.7 m11.9 m

Interest income

98 k137 k255 k646 k

Net Income

(4.7 m)(9.4 m)(15.7 m)(24.5 m)(23.1 m)(21.1 m)(18.7 m)(31.7 m)

Collegium Pharmaceutical Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

95.7 m153.2 m118.7 m

Accounts Receivable

2.1 m10 m

Inventories

1.2 m1.9 m1.8 m

Current Assets

96.9 m158.6 m133.5 m

PP&E

738 k1 m1.8 m

Total Assets

97.7 m162 m135.6 m

Accounts Payable

3.5 m9.1 m5.7 m

Current Liabilities

8.4 m25.6 m31.5 m

Total Liabilities

27.1 m31.5 m

Additional Paid-in Capital

214.1 m358.1 m402.1 m

Retained Earnings

(129 m)(223.2 m)(298 m)

Total Equity

85.1 m134.9 m104.1 m

Financial Leverage

1.1 x1.2 x1.3 x

Quarterly

USDQ3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

105.5 m110.7 m91 m129.6 m111.2 m128.2 m133.7 m

Accounts Receivable

3 m1.7 m3.3 m4.9 m66 m68.4 m

Inventories

1.2 m1.6 m1.5 m1.5 m7.9 m8.5 m

Current Assets

106.3 m116.5 m95.4 m136.5 m120.6 m207.7 m216.3 m

PP&E

627 k676 k772 k1 m1.6 m1.6 m3.2 m

Total Assets

107.1 m119.7 m98.7 m139.8 m124.5 m696.3 m673.3 m

Accounts Payable

3.2 m6.1 m9 m6.8 m5.6 m9.3 m18.7 m

Current Liabilities

8.6 m18.2 m22.2 m24.5 m28.6 m250.2 m264.7 m

Total Liabilities

13.5 m21.1 m24.4 m25.5 m29 m605.5 m590.6 m

Additional Paid-in Capital

213 m267.8 m269.9 m360.6 m362.9 m407.5 m412.4 m

Retained Earnings

(119.5 m)(169.2 m)(195.6 m)(246.3 m)(267.4 m)(316.7 m)(329.8 m)

Total Equity

93.6 m98.7 m74.3 m114.4 m95.5 m90.8 m82.7 m

Financial Leverage

1.1 x1.2 x1.3 x1.2 x1.3 x7.7 x8.1 x

Collegium Pharmaceutical Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(27.3 m)(94.2 m)(74.9 m)

Depreciation and Amortization

171 k655 k594 k

Accounts Receivable

(2.1 m)(7.8 m)

Inventories

(659 k)(1.3 m)(497 k)

Accounts Payable

1.3 m5.6 m(3.4 m)

Cash From Operating Activities

(21.6 m)(75.1 m)(67 m)

Purchases of PP&E

(362 k)(477 k)(990 k)

Cash From Investing Activities

(362 k)(3 m)(990 k)

Cash From Financing Activities

116 m135.6 m33.5 m

Interest Paid

353 k284 k139 k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(4.7 m)(17.7 m)(15.7 m)(24.5 m)(23.1 m)(44.2 m)(18.7 m)(31.7 m)

Depreciation and Amortization

130 k208 k332 k482 k

Accounts Receivable

3 m1.7 m(1.2 m)(2.7 m)(56.1 m)(58.4 m)

Inventories

1.2 m1.6 m(179 k)(204 k)134 k(508 k)

Accounts Payable

2.2 m962 k6.2 m6.1 m9 m(2.3 m)(3.5 m)3.7 m13 m

Cash From Operating Activities

(12.6 m)(23.7 m)(41.2 m)29.7 m85.3 m

Purchases of PP&E

(175 k)(29 k)(478 k)(356 k)(987 k)

Cash From Investing Activities

(175 k)(29 k)(478 k)(19.1 m)(19.9 m)

Cash From Financing Activities

116.6 m50 k(383 k)(388 k)(50.5 m)

Interest Paid

260 k49 k88 k109 k242 k

Income Taxes Paid

4 k

Collegium Pharmaceutical Ratios

USDY, 2018

Financial Leverage

8.1 x
Report incorrect company information